Aquestive Therapeutics Clears FDA Hurdle for Anaphylm Resubmission — Aquestive Therapeutics, Inc.

Event summary

Aquestive Therapeutics completed a Type A meeting with the FDA regarding the resubmission of its Anaphylm NDA.
FDA provided preliminary feedback on pharmacokinetic and human factors study designs.
Aquestive reaffirmed its guidance to resubmit the Anaphylm NDA in Q3 2026.
FDA acknowledged changes to the Anaphylm container closure design.
Final FDA meeting minutes expected by early May 2026.

The big picture

Aquestive Therapeutics' successful Type A meeting with the FDA marks a critical step in advancing Anaphylm, a potential first-of-its-kind oral epinephrine treatment. The alignment on key study designs and packaging improvements positions Aquestive to address a significant unmet need in severe allergic reactions. The company's ability to navigate regulatory feedback will be pivotal in determining the timeline and success of Anaphylm's approval and market entry.

What we're watching

Regulatory Alignment: Whether Aquestive can fully address FDA feedback on pharmacokinetic and human factors studies to ensure a smooth NDA resubmission process.
Market Differentiation: The pace at which Aquestive can position Anaphylm as the first and only oral epinephrine product, assuming FDA approval.
Execution Risk: How Aquestive manages the timing and success of its upcoming human factors and pharmacokinetic studies ahead of the Q3 2026 NDA resubmission.